News

Filter: Business Posts

MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress

MIT and CN Bio Innovations today announced that the world’s first 7-organ “Human-on-a-Chip” platform will be showcased at the Organ-on-Chip congress in Boston on the 7th and 8th of July 2016. Under a $26M Defense Advanced Research Projects Agency (DARPA) contract awarded to researchers at the Massachusetts Institute of Technology, Continuum LLC and CN Bio… Read more »

READ MORE

CN Bio Sponsors the Organ-On-Chip world congress in Boston

CN Bio Innovations Ltd, an expert in developing human organs-on-chips to test and develop therapeutics for serious diseases, is proud to be the platinum sponsor of SelectBio’s 2nd Annual Organ-on-a-Chip world Congress in Boston on the 7th and 8th of July. The conference brings together the world’s leading experts in Organ-on-chip technology from academia and… Read more »

READ MORE

CN Bio appoints Emma Sceats as CEO

CN Bio Innovations are delighted to announce the appointment of Dr Emma Sceats as Chief Executive effective 1st January 2016. Dr David Scales will remain on the board as an advisor to the company with particular emphasis on new business opportunities.

READ MORE

Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting

CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).

READ MORE

CN Bio appoints Dr David Hughes to board of directors

Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.

READ MORE

CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist. Simultaneous with the publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.

READ MORE

CN Bio Innovations announces LiverChip research study with leading pharmaceutical company

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research study with a fourth pharmaceutical company.

The program will take advantage of CN Bio’s human liver-on-a-chip platform, LiverChip, to study targets implicated in liver disease.

READ MORE

CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company

Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle… Read more »

READ MORE

CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals

CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc. Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN… Read more »

READ MORE

NIH Director highlights LiverChip in Compton Lecture

Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on October 28 at the Massachusetts Institute of Technology. In his lecture entitled “Exceptional Opportunities in Biomedical Research” Collins featured work by MIT Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering… Read more »

READ MORE

TSB Funds New Research by CN Bio into Fatty Liver Disease

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development of human in vitro models of Non-Alcoholic Fatty Liver Disease (NAFLD). CN Bio will partner on the award with UK-based CRO Xenogesis Ltd., which specialises in preclinical DMPK, quantitative bioanalysis… Read more »

READ MORE

Promotion of Dr David Hughes to the role of Chief Technology Officer

Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams. Dr Hughes joined the Company in 2010… Read more »

READ MORE

CN Bio appoints Professor Mark Thursz as Scientific Advisor

CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable experience and a deep knowledge of clinical hepatology and related non-clinical research and I believe that CN Bio will benefit from having access to Mark’s expertise as we continue to develop and… Read more »

READ MORE

CN Bio hires Director of Licensing

CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to facilitate the commercialization of CN Bio’s novel proprietary infectious disease models. Gavin brings with him over 35 years of experience in the pharmaceutical industry including roles as Global Licensing… Read more »

READ MORE

Liver disease to become a bigger killer than heart disease or cancer

Liver disease has the potential to become the UK’s biggest killer within a generation, is the stark assessment of an independent report released today by a group of politicians and liver experts. The damning report highlights the “scandalous” absence of a national strategy to tackle liver disease, the result of which is a “shameful waste of… Read more »

READ MORE